LMNA and Hutchinson-Gilford progeria syndrome: Among all the analyzed preclinical trials adopting therapeutic nucleic acids to treat HGPS, strategies that show higher practicability in the clinical context are antisense morpholino‐based therapy that prevents pathogenic LMNA splicing (Osorio et al., 2011) and antisense oligonucleotide therapy that increases lamin C production at the expense of prelamin A (Lee, Nobumori, et al., 2016).